Abstract |
Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated with iproplatin (CHIP). No objective responses were noted in any of the patients treated. By restricting the entry criteria to heavily pre-treated patients, the identification of new active agents in phase II trials may be hindered. Alternative strategies for the investigation of new agents in patients with GCT should be considered, particularly when studying the efficacy and relative toxicity of platinum analogues.
|
Authors | B A Murphy, R J Motzer, G J Bosl |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 10
Issue 4
Pg. 327-30
(Nov 1992)
ISSN: 0167-6997 [Print] United States |
PMID | 1336770
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Organoplatinum Compounds
- iproplatin
- Cisplatin
|
Topics |
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Cisplatin
(therapeutic use)
- Drug Resistance
- Humans
- Male
- Neoplasms, Germ Cell and Embryonal
(drug therapy)
- Organoplatinum Compounds
(adverse effects, therapeutic use)
|